Bio-Rad Laboratories, Inc. and NuProbe USA announced the signing of a licensing and product development agreement. Under the terms of the agreement, NuProbe USA will exclusively license its allele enrichment technologies to Bio-Rad for the development of multiplexed digital PCR assays. This technology will help to advance Bio-Rad's menu of products in oncology, where highly sensitive and multiplexed mutation detection assays aid translational research, therapy selection and disease monitoring.

NuProbe USA has developed and optimized the Blocker Displacement Amplification (BDA) technology as a PCR method in which variant DNA alleles are enriched over 1000-fold over wild-type alleles. The BDA technology has been featured in scientific publications and journals including Nature Biomedical Engineering and Nature Communications, and BDA has been experimentally validated on hundreds of clinical samples across multiple platforms including quantitative PCR, digital PCR, Sanger sequencing, sequencing-by-synthesis (NGS), and nanopore sequencing. Bio-Rad is a market leader in digital PCR and provides complete solutions to the research and diagnostics communities, including instrumentation, software, reagents and the most expansive menu of digital PCR assays on the market for applications spanning translational research, cell and gene therapy and environmental monitoring.

Droplet Digital PCR has been cited in over 6300 publications including more than 800 clinical research citations.